Sarcopenia Approximately 40% of the weight reduction associated with GLP-1 RAs is derived from a lean body mass, which raises significant concerns regarding its potential negative impact on skeletal muscle functionality [110]
Type 2 diabetes management : FDA-approved doses are calibrated for glycemic control
Do, D., Lee, T., Peasah, S
doi: 10.3892/ijmm.2013.1252 8
Despite likely being a similar tier as GLP-1 RAs and SGLT2is for many patient insurances, this elevated AWP is important to note for patients with co-insurances, deductibles, the Medicare coverage gap, patients without insurance, and for the total cost of healthcare
The single most significant driver for the GLP-1 receptor agonist market is the escalating global burden of obesity and metabolic syndrome